AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Study of Belimumab in the Prevention of Kidney Transplant Rejection

Phase 2

Completed

Conditions: Transplantation, Organ

Interventions: Drug: Placebo
Drug: Belimumab

First Posted Date: 2012-02-22

Last Posted Date: 2017-04-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 30

Registration Number: NCT01536379

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma, Non-Hodgkin

Interventions: Biological: Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas (Tositumomab and Iodine I 131 Tositumomab)

First Posted Date: 2012-02-22

Last Posted Date: 2017-08-31

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 59

Registration Number: NCT01536561

Belimumab (BENLYSTA®) Pregnancy Registry

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: belimumab

First Posted Date: 2012-02-14

Last Posted Date: 2025-06-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 77

Registration Number: NCT01532310

Locations: 🇨🇭
GSK Investigational Site, Zuerich, Switzerland

A Study to Evaluate the Pharmacokinetics of Benzoic Acid and Hippuric Acid After Topical Administration of GSK2585823 in Japanese Subjects With Acne Vulgaris

Phase 1

Completed

Conditions: Acne Vulgaris

Interventions: Drug: GSK2585823

First Posted Date: 2012-02-06

Last Posted Date: 2017-07-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 12

Registration Number: NCT01527123

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection

Phase 3

Completed

Conditions: Influenza, Human

Interventions: Drug: Intravenous (IV) zanamivir

First Posted Date: 2012-02-06

Last Posted Date: 2018-02-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 21

Registration Number: NCT01527110

Locations: 🇯🇵
GSK Investigational Site, Shizuoka, Japan

Assessment of Lung Function After Single Inhalations of a Bronchodilator From 2 Configurations a Dry Powder Inhaler.

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: GSK573719 62.5 mcg (one strip)
Drug: GSK573719 62.5 mcg(two strips)
Drug: GSK573719 125 mcg (one strip)
Drug: GSK573719 125 mcg(two strips)
Drug: Placebo